HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Undifferentiated Connective Tissue Diseases

Diseases that exhibit signs and symptoms suggestive of a connective tissue disease that do not fulfill clinical or diagnostic criteria for any one defined disease but overlap with criteria of multiple such diseases. Commonly overlapping diseases include systemic autoimmune connective tissue diseases such as RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; and SYSTEMIC SCLEROSIS.
Also Known As:
Undifferentiated Connective Tissue Disease
Networked: 132 relevant articles (2 outcomes, 14 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Dermatomyositis (Dermatopolymyositis)
2. Arthralgia (Joint Pain)
3. Hyperhidrosis
4. Calcinosis
5. Rheumatic Diseases (Rheumatism)

Experts

1. Bodolay, Edit: 6 articles (10/2015 - 02/2002)
2. Cutolo, Maurizio: 4 articles (01/2022 - 01/2008)
3. Valentini, Gabriele: 3 articles (11/2020 - 08/2012)
4. Shoenfeld, Yehuda: 3 articles (10/2020 - 01/2011)
5. Tincani, Angela: 3 articles (10/2020 - 01/2011)
6. Bombardieri, Stefano: 3 articles (01/2018 - 11/2002)
7. Mosca, Marta: 3 articles (01/2018 - 11/2002)
8. Szodoray, Peter: 3 articles (10/2015 - 01/2008)
9. Gyimesi, Edit: 3 articles (06/2013 - 01/2008)
10. Zeher, Margit: 3 articles (06/2013 - 12/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Undifferentiated Connective Tissue Diseases:
1. Diltiazem (Cardizem)FDA LinkGeneric
2. incobotulinumtoxinAFDA Link
3. AntibodiesIBA
4. CytokinesIBA
10/01/2015 - "Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review."
05/01/1995 - "To measure the levels of serum soluble CD30 (sCD30), a marker of cells producing T helper 2(Th2)-type cytokines, in systemic lupus erythematosus (SLE) and undifferentiated connective tissue disease (UCTD), and to determine its value in assessing disease activity. "
11/01/2010 - "The aim of this study was to perform a quantitative and functional analysis of natural CD4+CD25(high)Foxp3+ regulatory T cells (nTregs) and CD4+IL-17+ T cells, and to assess the serum levels of proinflammatory cytokines in patients with undifferentiated connective tissue disease (UCTD) before and after 5 weeks of 0.5 μg/day alfacalcidol supplementation. "
01/01/2023 - "Adult NA patients with autoantibody-positive (AAB+) rheumatoid arthritis (RA; n = 28), autoantibody negative (AAB-) RA (n = 18), systemic autoimmune rheumatic disease (n = 28), arthralgia/osteoarthritis (n = 28), or polyarthritis/undifferentiated connective tissue disease (n = 28), and control patients (n = 28) provided serum samples for cytokine, chemokine, and AAB assessment. "
01/01/2022 - "Recent evidence has shown T-cell-mediated inflammatory responses in cases of NMOSD.20 In particular, Th17 and Th2-related cytokines are elevated in the CSF of NMO patients.20 Environmental factors such as Escherichia coli have also been proven to aggravate autoimmunity in AS and NMOSD (however, body fluid cultures for Escherichia coli, performed in our patient, showed similar association, and they were found negative two times).21,22 Although large-scale epidemiological studies investigating the underlying pathogenesis related to these diseases are lacking, studies have demonstrated an increased incidence of optic neuritis among patients with AS.23 Systemic sclerosis and mixed and undifferentiated connective tissue diseases were excluded after expert opinions (from two board-certified rheumatologists and two dermatologists) because of the lack of suggestive clinical findings (e.g., absence of skin thickening, salt-and-pepper appearance, nail changes, Mauskopf facies, sclerodactyly, calcinosis cutis, Raynaud's phenomenon, other cutaneous manifestations, pulmonary arterial hypertension/interstitial lung disease, dysphagia, muscular pain/weakness renal impairments, absence of ANA, anti-centromere antibodies, anti-Scl-70, PM-Scl antibodies, anti-ds DNA, PCNA, CENP-B, anti-nucleosomes, anti-Smith, anti-U1-RNP, anti-Jo1, anti-Mi2, anti-Ro52, anti-La antibodies, and normal C3 and C4 complement levels) (The European League Against Rheumatism and the American College of Rheumatology classification criteria 2019).24 Finally, our patient was treated with intravenous steroids followed by rituximab infusions, a monoclonal anti-CD20 antibody directed against B-cells. "
5. AutoantibodiesIBA
6. Vitamin DFDA LinkGeneric
7. Antinuclear AntibodiesIBA
8. Hydroxychloroquine (Plaquenil)FDA LinkGeneric
9. Immunoglobulin G (IgG)IBA
10. ImmunosorbentsIBA

Therapies and Procedures

1. Therapeutics
2. Aftercare (After-Treatment)
3. Injections
4. Lasers (Laser)
5. Renal Dialysis (Hemodialysis)